questionsmedicales.fr
Composés polycycliques
Hydrocarbures aromatiques polycycliques
Naphtalènes
1,2,3,4-Tétrahydro-naphtalènes
7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol
7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol : Questions médicales fréquentes
Diagnostic
5
Intoxication
Symptômes cliniques
Tests de laboratoire
Exposition
Marqueurs biologiques
Composé chimique
Évaluation neurologique
Psychologie
Symptômes
5
Symptômes
Exposition aiguë
Effets psychologiques
Anxiété
Symptômes neurologiques
Convulsions
Troubles cognitifs
Mémoire
Prévention
5
Prévention
Équipements de protection
Formation
Produits chimiques
Sensibilisation
Campagnes d'information
Réglementations
Industrie
Traitements
5
Antidote
Composé chimique
Thérapie psychologique
Médicaments
Soins neurologiques
Suivi médical
Complications
5
Dépendance
Utilisation prolongée
Gestion des complications
Suivi médical
Effets secondaires
Neurologiques
Troubles de l'humeur
Troubles anxieux
Facteurs de risque
5
Facteurs de risque
Travailleurs
Prédispositions génétiques
Sensibilité
Environnement de travail
Exposition
Antécédents médicaux
Troubles neurologiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol : Questions médicales les plus fréquentes",
"headline": "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2026-02-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "1,2,3,4-Tétrahydro-naphtalènes",
"url": "https://questionsmedicales.fr/mesh/D013764",
"about": {
"@type": "MedicalCondition",
"name": "1,2,3,4-Tétrahydro-naphtalènes",
"code": {
"@type": "MedicalCode",
"code": "D013764",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.638.960"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"alternateName": "8-Hydroxy-2-(di-n-propylamino)tetralin",
"code": {
"@type": "MedicalCode",
"code": "D017371",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yu Zhang",
"url": "https://questionsmedicales.fr/author/Yu%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Food Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China."
}
},
{
"@type": "Person",
"name": "Altaf A Kondkar",
"url": "https://questionsmedicales.fr/author/Altaf%20A%20Kondkar",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia."
}
},
{
"@type": "Person",
"name": "Tahira Sultan",
"url": "https://questionsmedicales.fr/author/Tahira%20Sultan",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia."
}
},
{
"@type": "Person",
"name": "Taif A Azad",
"url": "https://questionsmedicales.fr/author/Taif%20A%20Azad",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia."
}
},
{
"@type": "Person",
"name": "Essam A Osman",
"url": "https://questionsmedicales.fr/author/Essam%20A%20Osman",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Using 8-Hydroxy-2'-Deoxiguanosine (8-OHdG) as a Reliable Biomarker for Assessing Periodontal Disease Associated with Diabetes.",
"datePublished": "2024-01-24",
"url": "https://questionsmedicales.fr/article/38338704",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25031425"
}
},
{
"@type": "ScholarlyArticle",
"name": "DNA oxidative damage in oral cancer: 8-hydroxy-2´-deoxyguanosine immunoexpression assessment.",
"datePublished": "2023-11-01",
"url": "https://questionsmedicales.fr/article/37471300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4317/medoral.25924"
}
},
{
"@type": "ScholarlyArticle",
"name": "8-hydroxy-2'-deoxyguanosine, a biomarker of oxidative DNA injury, in diabetic kidney disease.",
"datePublished": "2024-08-24",
"url": "https://questionsmedicales.fr/article/39271385",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.numecd.2024.08.015"
}
},
{
"@type": "ScholarlyArticle",
"name": "A comparative meta-analysis of peripheral 8-hydroxy-2'-deoxyguanosine (8-OHdG) or 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG) levels across mood episodes in bipolar disorder.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36931055",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.psyneuen.2023.106078"
}
},
{
"@type": "ScholarlyArticle",
"name": "Asymmetric Total Synthesis of 4-Hydroxy-8-",
"datePublished": "2024-07-22",
"url": "https://questionsmedicales.fr/article/39037742",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.joc.4c01393"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Naphtalènes",
"item": "https://questionsmedicales.fr/mesh/D009281"
},
{
"@type": "ListItem",
"position": 5,
"name": "1,2,3,4-Tétrahydro-naphtalènes",
"item": "https://questionsmedicales.fr/mesh/D013764"
},
{
"@type": "ListItem",
"position": 6,
"name": "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"item": "https://questionsmedicales.fr/mesh/D017371"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Comment diagnostiquer une intoxication au dipropylamino-5,6,7,8-tétrahydro-1-naphtol ?\nQuels tests peuvent confirmer l'exposition à ce composé ?\nQuels signes cliniques sont associés à une surdose ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment évaluer l'impact neurologique ?",
"url": "https://questionsmedicales.fr/mesh/D017371#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Quels sont les symptômes d'une exposition aiguë ?\nPeut-on observer des effets psychologiques ?\nQuels symptômes neurologiques peuvent apparaître ?\nY a-t-il des symptômes à long terme ?\nComment les symptômes varient-ils selon la dose ?",
"url": "https://questionsmedicales.fr/mesh/D017371#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Comment prévenir l'exposition au dipropylamino ?\nY a-t-il des formations recommandées ?\nQuels sont les conseils pour les travailleurs exposés ?\nComment sensibiliser le public aux risques ?\nQuelles réglementations existent pour ce composé ?",
"url": "https://questionsmedicales.fr/mesh/D017371#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes spécifiques existent-ils ?\nComment gérer les symptômes psychologiques ?\nQuels soins sont nécessaires pour les effets neurologiques ?\nY a-t-il des traitements préventifs ?",
"url": "https://questionsmedicales.fr/mesh/D017371#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Quelles complications peuvent survenir après une surdose ?\nY a-t-il des risques de dépendance ?\nComment les complications sont-elles gérées ?\nDes effets secondaires à long terme sont-ils possibles ?\nQuelles sont les complications psychologiques possibles ?",
"url": "https://questionsmedicales.fr/mesh/D017371#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol",
"description": "Quels sont les principaux facteurs de risque d'exposition ?\nL'âge influence-t-il le risque d'effets ?\nY a-t-il des prédispositions génétiques ?\nComment l'environnement de travail affecte-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D017371#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication au dipropylamino-5,6,7,8-tétrahydro-1-naphtol ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et les symptômes cliniques observés."
}
},
{
"@type": "Question",
"name": "Quels tests peuvent confirmer l'exposition à ce composé ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et urinaires peuvent détecter la présence de ce composé."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une surdose ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent agitation, hallucinations et troubles moteurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de marqueurs biologiques spécifiques pour ce composé."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact neurologique ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens neurologiques et des évaluations psychologiques sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vertiges et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Peut-on observer des effets psychologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets tels que l'anxiété et la dépression peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tremblements, des convulsions et des troubles de la mémoire peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes à long terme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles cognitifs et des problèmes de mémoire peuvent persister."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon la dose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une dose plus élevée entraîne des symptômes plus graves et plus variés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au dipropylamino ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations sur la manipulation sécurisée des produits chimiques sont conseillées."
}
},
{
"@type": "Question",
"name": "Quels sont les conseils pour les travailleurs exposés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils doivent porter des protections et signaler toute exposition immédiate."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser le public aux risques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des ateliers peuvent être organisés."
}
},
{
"@type": "Question",
"name": "Quelles réglementations existent pour ce composé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réglementations strictes encadrent son utilisation dans l'industrie."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement consiste en des soins de soutien et une surveillance médicale étroite."
}
},
{
"@type": "Question",
"name": "Des antidotes spécifiques existent-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique pour ce composé."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes psychologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies psychologiques et des médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels soins sont nécessaires pour les effets neurologiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation neurologique et un suivi régulier sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'éducation et la réduction de l'exposition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une surdose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et psychologiques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de dépendance ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une utilisation prolongée peut entraîner des risques de dépendance psychologique."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles nécessitent un suivi médical et des interventions adaptées."
}
},
{
"@type": "Question",
"name": "Des effets secondaires à long terme sont-ils possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires neurologiques peuvent persister longtemps."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications psychologiques possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de l'humeur et des troubles anxieux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et ceux manipulant des produits chimiques sont à risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'effets ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes et les personnes âgées peuvent être plus vulnérables."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux effets."
}
},
{
"@type": "Question",
"name": "Comment l'environnement de travail affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement mal ventilé ou non sécurisé augmente le risque d'exposition."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de troubles neurologiques peuvent accroître le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/02/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Food Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Glaucoma Research Chair in Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Glaucoma Research Chair in Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Institute of Environmental Health, Wuhan Centers for Disease Control and Prevention, Wuhan, Hubei 430024, PR China. Electronic address: yanjian.wan@whcdc.org.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
DNA Damage Laboratory of Food Science Department, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
DNA Damage Laboratory of Food Science Department, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
DNA Damage Laboratory of Food Science Department, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
DNA Damage Laboratory of Food Science Department, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Centro de Tecnologia da Informação Renato Archer, CTI, Rod. D. Pedro I, KM 143.6, 13069-901, Campinas, SP, Brazil.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Centro de Tecnologia da Informação Renato Archer, CTI, Rod. D. Pedro I, KM 143.6, 13069-901, Campinas, SP, Brazil.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Centro de Tecnologia da Informação Renato Archer, CTI, Rod. D. Pedro I, KM 143.6, 13069-901, Campinas, SP, Brazil.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Centro de Tecnologia da Informação Renato Archer, CTI, Rod. D. Pedro I, KM 143.6, 13069-901, Campinas, SP, Brazil.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
CDMF, Universidade Federal de São Carlos, P.O. Box 676, São Carlos, SP, 13565-905, Brazil.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Centro de Tecnologia da Informação Renato Archer, CTI, Rod. D. Pedro I, KM 143.6, 13069-901, Campinas, SP, Brazil. talita.mazon@cti.gov.br.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
National Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat Street, Cluj-Napoca 400293, Romania.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
National Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat Street, Cluj-Napoca 400293, Romania.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Electrochemistry and PATLAB, National Institute of Research for Electrochemistry and Condensed Matter, 202 Splaiul Independentei Street, Bucharest-6 060021, Romania.
Faculty of Applied Chemistry and Material Science, Politehnica University of Bucharest, Bucharest RO-060042, Romania.
Publications dans "7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol" :
In recent years, research has shown that oxidative stress plays a significant role in chronic inflammatory conditions. The alteration of the oxidant/antioxidant balance leads to the appearance of free...
The development and establishment of oral squamous cell carcinoma are confined to carcinogenesis, which involves oxidative stress via oxygen-free radical production as a hydroxyl radical (HO•), consid...
We collected 30 paraffin-embedded tissue samples of OSCC from patients treated between 2013 and 2018. We recorded risk habits, disease stage, disease free survival and death with at least 3 years of f...
Most of the cases expressed 8-OHdG with a strong intensity (80%). All neoplastic cells were preferentially stained in only the cytoplasm (70.0%), but nuclear positivity was found in 30%, independent o...
All tumors showed DNA oxidative damage, and 8-OHdG was preferentially expressed in the cytoplasm. This finding was associated with tumor size and, when present in the nucleus, might also be related to...
To gain insight into the extent of oxidative stress and DNA damage in diabetic kidney disease (DKD), a serious complication of diabetes, we compared the levels of the oxidative stress-related metaboli...
We analyzed serum 8-OHdG in relation to clinical indicators of kidney function in a group of type-2 diabetes patients including 33 patients with DKD and 33 without DKD. Circulating levels of 8-OHdG we...
This study supports the role of oxidative stress in the pathogenesis of diabetic nephropathy and highlights the potential of serum 8-OHdG as a biomarker for assessing oxidative stress and DNA damage i...
Oxidative DNA damage has been associated with the pathophysiology of bipolar disorder (BD) as one of the common pathways between increased medical comorbidity and premature aging in BD. Previous evide...
A literature search was conducted using the databases PubMed, Scopus, and Web of Science to identify eligible studies (January 1989 to July 2022). Relevant studies were systematically reviewed; a rand...
The current meta-analysis included 12 studies consisting of 808 BD patients (390 in euthymia, 156 in mania, 137 in depression, 16 in mixed episode, 109 not specified) and 563 healthy controls. BD pati...
Our findings suggest that 8-OHdG/8-oxo-dG may be a state-related marker of depression in BD and may be affected by older age and female gender....
Herein, we report the first asymmetric total synthesis of 4-hydroxy-8-...
Myeloproliferative neoplasms (MPNs), namely, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal stem cell disorders defined by an excessive production ...
Hyperlipidemia is a common risk factor for atherosclerosis, heart diseases, and other pathological conditions. The factors leading to the oxidation of native low-density lipoproteins remain of valuabl...
One hundred and fourteen participants were enrolled. Lipid profile parameters were measured and used individually to categorize subjects into two groups of normal and hyperlipidemic cases according to...
8-Hydroxy-2´-deoxyguanosine was found to be positively correlated with hypercholesterolemia, hypertriglyceridemia, and high levels of low-density lipoproteins (r = 0.53, 0.41, and 0.60), respectively ...
The present study suggests that disturbance in lipid profile may result in increased levels of oxidized low-density lipoproteins and oxidative stress in the study group; however, a larger sample is ne...
The International Agency for Research on Cancer has classified arsenic as a class I carcinogen. Oxidative DNA damage is a typical early precursor to recognized malignancies. The most sensitive early i...
This study was aimed at exploring the effects of urinary arsenic on 8-OHdG in human urine....
A literature search until January 2023 was performed on the PubMed, Cochrane Library, Web of Science, Embase, and Scopus databases through a combination of computer and manual retrieval. Stata 12.0 wa...
This meta-analysis included nine studies, most of which were performed in China. After exposure to arsenic, urinary arsenic (per 10 μg/g creatinine increase) was associated with the increased 8-OHdG (...
The 8-OHdG levels in human urine significantly increased after exposure to environmental arsenic, thus suggesting that arsenic exposure is correlated with oxidative DNA damage....
The relationships between stress hormones and oxidative DNA damage have not yet been explored in human hypertension. We investigated the associations of urinary levels of cortisol or catecholamines wi...
Untreated 156 primary hypertensives without apparent cardiovascular diseases were entered into the study. Following blood sampling after an overnight fast, 24-h blood pressure monitoring and 24-h urin...
Urinary cortisol significantly correlated positively with urinary 8-hydroxy-2'-deoxyguanosine in all studied participants (r = 0.334, P < 0.001). Contrary, either urinary adrenaline or urinary noradre...
The present study suggested the possibility that the overactivation of hypothalamic-pituitary-adrenal axis rather than sympathoadrenal system could enhance oxidative stress and attendant DNA oxidation...
DNA is an important target for oxidative attack and its modification may increase the risk of mutagenesis. The aim of this study was to evaluate and compare salivary levels of the oxidative stress bio...
The present systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and was registered in Open Science Framework (OSF): ...
Of the 166 articles identified, 130 articles were excluded on the basis of title and abstract screening (duplicates, reviews, etc.). Thirty-six articles were evaluated at full text and 7 articles met ...
This systematic review and meta-analysis suggests a clear trend of increased 8-OHdG levels in saliva of OC patients compared to the control group. However, further studies are required to clarify and ...